p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer

Yang Li; Giulio Francia; Jian-Ying Zhang

doi:10.18632/oncotarget.5328

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer

Yang Li _, Giulio Francia and Jian-Ying Zhang

PDF | HTML | How to cite

Oncotarget. 2015; 6:32656-32668. https://doi.org/10.18632/oncotarget.5328

Metrics: PDF 2494 views | HTML 3530 views | ?

Abstract

Yang Li1, Giulio Francia1, Jian-Ying Zhang1

1Department of Biological Sciences & NIH-Sponsored Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA

Correspondence to:

Jian-Ying Zhang, e-mail: [email protected]

Giulio Francia, e-mail: [email protected]

Keywords: breast cancer, IGF2 mRNA binding protein 2, cell migration, cell adhesion, extracellular matrix

Received: May 05, 2015 Accepted: September 11, 2015 Published: September 23, 2015

ABSTRACT

p62/IMP2 is an oncofetal protein that is overexpressed in several types of cancer, and is a member of the family of insulin-like growth factor 2 mRNA binding proteins. We previously reported that high levels of p62/IMP2 autoantibody are present in sera from cancer patients, compared to healthy individuals. Here, we report the overexpression of p62/IMP2 in tumor tissues of 72 out of 104 cases of human breast cancer, and high levels of p62/IMP2 autoantibody in patients’ sera (in 63 out of 216 cases). To explore the role of p62/IMP2 in breast cancer progression, we generated p62/IMP2 transfected variants of two human breast cancer cell lines: MDA-MB-231 and LM2-4. Using in vitro assays we found that overexpression of p62/IMP2 can increase cell migration, and reduce cell adhesion to extracellular matrix (ECM) proteins. A Human Extracellular Matrix and Adhesion Molecules qPCR array was performed with our generated variants, and it identified a group of mRNAs whose expression was altered with p62/IMP2 overexpression, including connective tissue growth factor (CTGF) mRNA – which we show to be a p62/IMP2 binding partner. Overall, our results provide new insights into the molecular mechanism by which p62/IMP2 can contribute to breast cancer progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5328

Publication Alerts

Research Papers:

p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer

Abstract